GIS
44
-3
SO
62
-4
STZ
35
-12
VRSK
70
-3
MLM
57
3
AMZN
55
3
SWKS
44
-9
SWK
25
-2
PNW
63
-3
CI
66
-7
D
32
4
FMC
29
-11
KMX
43
3
MCK
78
-2
KHC
27
-4
LLY
53
-17
MSI
58
-6
HST
40
2
NEE
38
-4
JWN
53
-2
GIS
44
-3
SO
62
-4
STZ
35
-12
VRSK
70
-3
MLM
57
3
AMZN
55
3
SWKS
44
-9
SWK
25
-2
PNW
63
-3
CI
66
-7
D
32
4
FMC
29
-11
KMX
43
3
MCK
78
-2
KHC
27
-4
LLY
53
-17
MSI
58
-6
HST
40
2
NEE
38
-4
JWN
53
-2
Financhill
Back

Lineage Cell Therapeutics 10K Form

Sell
36

LCTX
Lineage Cell Therapeutics

Last Price:
$0.50
Seasonality Move:
-2.47%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LCTX News And Ratings

See the #1 stock for the next 7 days that we like better than LCTX

LCTX Financial Statistics

Sales & Book Value

Annual Sales: $9.5M
Cash Flow: $-6.7M
Price / Cash Flow: 0
Annual Sales: $0.36
Price / Book: 1.47

Profitability

EPS (TTM): -0.10000
Net Income (TTM): $-18.6M
Gross Margin: $9.2M
Return on Equity: -27.23%
Return on Assets: -17.82%

Lineage Cell Therapeutics Earnings Forecast

Key Lineage Cell Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 33 years for LCTX is 96.48%.
  • The Selling, General & Administrative Expenses for LCTX have been equal to 191.29% of Gross Profit Margin.
  • The Research & Development expenses have been 131.30% of Revenue.
  • The Net Earning history of LCTX is -195.90% of Total Revenues.
  • Per Share Earnings over the last 33 years have been positive in 15 years.

Lineage Cell Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: LCTX
CUSIP: 53566P
Website: lineagecell.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.65
Quick Ratio: 3.47

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LCTX Technical Analysis vs Fundamental Analysis

Sell
36
Lineage Cell Therapeutics (LCTX) is a Sell

Is Lineage Cell Therapeutics a Buy or a Sell?